A large-scale clinical trial conducted by the World Health Organization has determined that Gilead Sciences Inc.’s remdesivir had little or no effect on COVID-19 patients’ chances of survival or length of hospital stay. The antiviral drug had been granted Emergency Use Authorization (EUA) by the Food and Drug Administration in
On September 22, 2020, the United States marked a grim milestone in the ongoing COVID-19 pandemic, with the coronavirus having killed its 200,000th victim. The number of American casualties currently stands at 203,800, the highest of any single nation in the world, with the U.S. suffering over one-fifth of the
Health officials in both Russia and around the world are raising concerns over Moscow’s approval of a vaccine to be used against the SARS-CoV-2 coronavirus, despite not having finished critical Phase 3 clinical trials for the new treatment necessary to determine both the effectiveness and safety of the new inoculation.
Medical research teams in England and China are reporting that COVID-19 vaccines being developed are prompting a protective immune response against the coronavirus in subjects that have been injected with the new formulations. This is good news, as other researchers have found that the antibodies produced from a direct infection